HeyJaredZachary Klaassen
- Indexed articles, last 90 days
- 14
- Latest publication
- Sep 6, 2026
- Outlet visibility, for Urotoday
- Top 1M sites
- Earliest in this view
- Sep 4, 2026
Latest articles
ProsTIC26: New Targets: What will be the next PSMA? (opens the original)
Read excerpt
(UroToday.com) The 2026 ProsTIC annual meeting featured an optimizing theranostics session and a presentation by Dr. Andrei Iagaru discussing new targets and what will be the next PSMA. For 2026, prostate cancer is projected to account for 333,830 new cancer diagnoses among men in the United States, representing 31% of male cancers. Prostate cancer is also projected to result in 36,320 deaths, accounting for 11% of male cancer deaths. Thus, despite substantial advances in detection and treatment
ProsTIC26: PSMA PET for Risk Stratification (opens the original)
Read excerpt
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Andrei Iagaru discussing PSMA PET for risk stratification. Dr. Iagaru began by defining risk stratification as the process of grouping patients according to their likelihood of experiencing a particular outcome, thereby helping clinicians determine the appropriate level of care, monitoring, or intervention. The concept is familiar throughout medicine: patients are not simply diagnosed with a
ProsTIC26: The Benefits of Post Therapy SPECT/CT over PET/CT (opens the original)
Read excerpt
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Grace Kong discussing the benefits of post therapy SPECT/CT over PET/CT. For this talk, Dr. Kong framed the presentation around the need to determine whether a patient is responding during a planned course of 177Lu-PSMA, typically delivered over six cycles at 6-week intervals. Conventional assessment incorporates clinical response, PSA, and imaging response criteria such as RECIST/PCWG3, but
ProsTIC26: Keynote: PSMA PET/CT and the Future of Prostate Cancer Trial Imaging (opens the original)
Read excerpt
(UroToday.com) The 2026 ProsTIC annual meeting featured a Keynote Address presentation by Dr. Alicia Morgans discussing PSMA PET/CT and the future of prostate cancer trial imaging. Dr. Morgans started her presentation by emphasizing that the framework for assessing prostate cancer in clinical trials has evolved substantially over the past several decades. The original PSA Working Group in 1999 established PSA endpoints. PCWG2 in 2008 subsequently incorporated the 2+2 bone scan rule and RECIST as
ProsTIC26: PSMA PET/CT for Diagnosis: PRIMARY2 study (opens the original)
Read excerpt
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Daniel Moon discussing the PRIMARY 2 study. mpMRI has become an important component of the prostate cancer diagnostic pathway, but uncertainty remains regarding the optimal management of men with equivocal MRI findings or those with a nonsuspicious MRI who nonetheless have persistent clinical features concerning for prostate cancer. In these patients, MRI alone may not provide sufficient conf
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For Urotoday, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.